Przegląd Dermatologiczny

Pełna treść

2/2026 vol. 113
Opis przypadku

Rituximab in Severe Mucocutaneous Pemphigus Vulgaris Complicated by Sepsis: a Difficult Path to Disease Control

Anna Wojas-Pelc 1, 2
,
Mirella Brzozowska 2
,
Arletta Kozłowska 2
,
Przemysław Hałubiec 1, 2, 3
,
Bartosz Obtułowicz 4
,
Andrzej K. Jaworek 1, 2

  1. Department of Dermatology, Jagiellonian University Medical College, Krakow, Poland

  2. Clinical Department of Dermatology and Allergology, University Hospital, Krakow, Poland

  3. Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Krakow, Poland

  4. Students’ Dermatology Research Association, Jagiellonian University Medical College, Krakow, Poland

Dermatol Rev/Przegl Dermatol 2026, 113, 102–106

DOI: https://doi.org/10.5114/dr.2026.163240
Data publikacji online: 2026/07/31
Plik artykułu
Rituximab in Severe.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Ingold C.J., Sathe N.C., Khan M.A.B.: Pemphigus vulgaris. In: StatPearls. Treasure Island: StatPearls Publishing 2025.
  2. Dmochowski M., Jałowska M., Bowszyc-Dmochowska M.: Issues occupying our minds: nomenclature of autoimmune blistering diseases requires updating; pemphigus vulgaris propensity to affect areas adjacent to natural body orifices unifies seemingly diverse clinical features of this disease. Front Immunol 2022, 13, 1103375.
  3. Porro A.M., Seque C.A., Ferreira M.C.C., Enokihara M.M.S.E.S.: Pemphigus vulgaris. An Bras Dermatol 2019, 94, 264-278.
  4. Kasperkiewicz M., Ellebrecht C.T., Takahashi H., Yamagami J., Zillikens D., Payne A.S., et al.: Pemphigus. Nat Rev Dis Primers 2017, 3, 17026.
  5. Kowalewski C., Dmochowski M., Placek W., Waszczykowska E., Nowicki R., Flisiak I., et al.: Diagnosis and therapy of pemphigus – consensus of Polish Dermatological Society. Dermatol Rev 2014, 101, 147-155.
  6. Joly P., Horvath B., Patsatsi A., Uzun S., Bech R., Beissert S., et al.: Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol 2020, 34, 1900-1913.
  7. Dickson S.: Observations on pemphigus. Lond Med J 1788, 9, 309-324.
  8. Beutner E.H., Jordon R.E.: Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med 1964, 117, 505-510.
  9. Amagai M., Klaus-Kovtun V., Stanley J.R.: Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991, 67, 869-877.
  10. Pile H.D., Yarrarapu S.N.S., Crane J.S.: Drug-induced pemphigus. In: StatPearls. Treasure Island: StatPearls Publishing 2023.
  11. Kajdas A.A., Żebrowska A., Zalewska-Janowska A., Czerwonogrodzka-Senczyna A.: The role of nutrition in the pathogenesis and treatment of autoimmune bullous diseases: a narrative review. Nutrients 2024, 16, 3961.
  12. Subadra K., Sathasivasubramanian S., Warrier S.A.: Oral pemphigus vulgaris. Cureus 2021, 13, e18005.
  13. Ran N.A., Payne A.S.: Rituximab therapy in pemphigus and other autoantibody-mediated diseases. F1000Res 2017, 6, 83.
  14. McClatchy J., Yap T., Koo K., Kern J.S., Scardamaglia L.: De-escalation of anti-CD20 monoclonal antibody rituximab protocols in pemphigus vulgaris: a systematic review. Expert Opin Biol Ther 2021, 21, 1591-1601.
  15. Sar-Pomian M., Konop M., Gala K., Rudnicka L., Olszewska M.: Scalp involvement in pemphigus: a prognostic marker. Adv Dermatol Allergol 2018, 35, 293-298.
  16. Joly P., Maho-Vaillant M., Prost-Squarcioni C., Hebert V., Houivet E., Calbo S., et al.: First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus: a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 2017, 389, 2031-2040.
  17. Spałek M.M., Jałowska M., Bowszyc-Dmochowska M., Dmochowski M.: Rituximab in the management of autoimmune bullous diseases: a treatment-resistant case series from a single Central European referral center. Medicina (Kaunas) 2024, 60, 270.
  18. Szymanski K., Kowalewski C., Walecka I., Wozniak K.: Eight years of follow-up of rituximab in pemphigus vulgaris and foliaceus at a single center: assessing efficacy and safety in light of several factors. J Clin Med 2025, 14, 7318.
  19. Rashid H., Poelhekken M., Meijer J.M., Bolling M.C., Horváth B.: The positive impact of rituximab on the quality of life and mental health in patients with pemphigus. JAAD Int 2022, 7, 31-33.
  20. Emer J.J., Wolinsky C.: Rituximab. J Clin Aesthet Dermatol 2009, 2, 29-37.
  21. Kelesidis T., Daikos G., Boumpas D., Tsiodras S.: Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 2011, 15, e2-e16.
  22. Anandan V., Jameela W.A., Sowmiya R., Kumar M.M.S., Lavanya P.: Rituximab: a magic bullet for pemphigus. J Clin Diagn Res 2017, 11, WC01-WC06.
  23. Kridin K., Mruwat N., Amber K.T., Ludwig R.J.: Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. Br J Dermatol 2023, 188, 499-505.
Copyright: © 2026 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
ZGŁASZANIE PRAC
Indeks osobowy
Udostępnij
without publication fees
without publication fees
Dostępne w
Zintergrowane z
plagiat pl
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications